BMT-06: Study of Intensity Modulated Total Marrow Irradiation (IM-TMI) (NCT04187105)
BMT-06: Phase II Study of Intensity Modulated Total Marrow Irradiation (IM-TMI) in Addition to Fludarabine/Cyclophosphamide and Post-Transplant Cyclophosphamide Conditioning for Partially HLA Mismatched Allogeneic Transplantation in Patients With Acute Leukemia and Myelodysplastic Syndrome (MDS)
🩺 Plain-English Summary (8th-Grade Level)
This study is being done to see if the addition of a targeted form of radiation to standard conditioning regimen will increase the amount of cancer cells that are killed off in the bone marrow and reduce the chances that your disease may return. This description is called Intensity Modulated Total Marrow Irradiation (IM-TMI).
Who can join: Review the eligibility criteria below.
Location: University of Illinois Cancer Center — Chicago, Illinois
Age range: 18 Years to 75 Years
🧪 Interventions in This Study
- Conditioning regimen with half-matched (haploidentical) stem cell transplant (DRUG)
- Conditioning regimen with half-matched (haploidentical) stem cell transplant (DRUG)
- Conditioning regimen with half-matched (haploidentical) stem cell transplant (DEVICE)
- Conditioning regimen with half-matched (haploidentical) stem cell transplant (DRUG)
- Conditioning regimen with half-matched (haploidentical) stem cell transplant (DRUG)
- Conditioning regimen with half-matched (haploidentical) stem cell transplant (DRUG)
- Conditioning regimen with half-matched (haploidentical) stem cell transplant (DRUG)
- Conditioning regimen with half-matched (haploidentical) stem cell transplant (DRUG)
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (1 Sites)
- University of Illinois Cancer Center — Chicago, Illinois
📞 Contact the Study Coordinator
Phone: (312) 996-6179
Email: drond@uic.edu
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Acute Leukemia
- Cytogenetic Studies in Acute Leukemia and Multiple Myeloma — La Jolla, California
- ATG Plus PTCy vs ATG for CGVHD Prophylaxis — Darlinghurst, New South Wales
- Cancer Stem Cells in Acute Leukemia — Fargo, North Dakota
- A High Intensity Electronic Health Intervention for the Reduction of Learning Disparities in Childhood Cancer Survivors — Duarte, California
- Prevention of Hospital Acquired Deconditioning in Hospitalized Acute Leukemia Patients — Manhasset, New York
- A First-in-Human Study of HLA-Partially to Fully Matched Allogenic Cryopreserved Deceased Donor Bone Marrow Transplantation for Patients With Hematologic Malignancies — Duarte, California
Explore by condition: All Acute Leukemia clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.